This study identifies two IgG immunodominant regions on the SARS-CoV-2 spike glycoprotein recognized by sera from COVID-19 convalescent patients. One region is SARS-CoV-2 specific and near the receptor-binding domain; the other, located at the fusion peptide, may be a pan-SARS target. Antibody depletion assays show that antibodies targeting these regions significantly enhance neutralization capacities, providing insights for therapeutic and vaccine design.
Publisher
Nature Communications
Published On
Oct 26, 2020
Authors
Chek Meng Poh, Guillaume Carissimo, Bei Wang, Siti Naqiah Amrun, Cheryl Yi-Pin Lee, Rhonda Sin-Ling Chee, Siew-Wai Fong, Nicholas Kim-Wah Yeo, Wen-Hsin Lee, Anthony Torres-Ruesta, Yee-Sin Leo, Mark I-Cheng Chen, Seow-Yen Tan, Louis Yi Ann Chai, Shirin Kalimuddin, Shirley Seek Geh Kheng, Siew-Yee Thien, Barnaby Edward Young, David C. Lye, Brendon John Hanson, Cheng-I Wang, Laurent Renia, Lisa F. P. Ng
Tags
SARS-CoV-2
spike glycoprotein
immunodominant regions
neutralization
antibody depletion
therapy
vaccine design
Related Publications
Explore these studies to deepen your understanding of the subject.
